Clinical Trial

A Feasibility Study of Mass-Based Response Drug Screening to Guide Personalized Hyperthermic Intraperitoneal Chemotherapy for High-Grade Appendiceal and Colorectal Adenocarcinoma With Peritoneal Metastasis

Recruiting
View on ClinicalTrials.gov →
Summary
This study will evaluate the role of mass-based response testing (MRT) to select and deliver personalized hyperthermic intraperitoneal chemotherapy (HIPEC) regimens to patients with peritoneal metastasis (PM) from high-grade appendiceal adenocarcinomas (HGAA) and colorectal cancer (CRC).
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2025-12-17; most recent amendment 2026-07-17.
Status change: Not Yet Recruiting → Recruiting 2026-03-02
Trial Details
NCT Number NCT07291180
Lead Sponsor Yale University
Collaborators: Travera Inc
Conditions Appendiceal Cancer, Colorectal Adenocarcinoma, Peritoneal Metastases
Enrollment 20 participants
Start Date 2026-02-17
Primary Completion 2027-10 (estimated)
Study Completion 2027-12 (estimated)
Updated on ClinicalTrials.gov 2026-07-21